Article ; Online: Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.
2023 Volume 86, Issue 4, Page(s) 263–276
Abstract: Background: The SARS-CoV-2 pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over the world. Understanding the risk of this disease is of high importance in patients with multiple ... ...
Abstract | Background: The SARS-CoV-2 pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over the world. Understanding the risk of this disease is of high importance in patients with multiple sclerosis (MS) as they represent a vulnerable population through their treatment with disease-modifying therapies (DMTs). Infective episodes may trigger relapses and lead to deterioration of the health condition. Summary: Vaccination is an important preventive measure against infectious diseases. In MS patients, concerns have been raised about the effectiveness of vaccines in patients on various immunomodulatory drugs and about their possible adverse effects including impairment of neurological functions. The objectives of this article were to summarize the current knowledge on immune responses to the COVID-19 vaccines and their safety in MS patients and to provide practical guidance based on the data available to date. Key messages: Although MS is not associated with a higher risk of COVID-19, this infection can trigger relapses or pseudo-relapses. Vaccines against SARS-CoV-2 are recommended for all MS patients who are not in the active phase of the disease, despite the fact that there is still a lack of long-term reliable data on the effectiveness and safety of vaccines against COVID-19. Some DMTs can reduce vaccine humoral responses, but might still provide some protection and adequate T-cell response. To optimize the effectiveness of vaccination, the ideal timing of vaccine application and DMTs dosing regimen is crucial. |
---|---|
MeSH term(s) | Humans ; COVID-19 Vaccines/adverse effects ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy ; COVID-19/prevention & control ; SARS-CoV-2 ; Vaccination/adverse effects |
Chemical Substances | COVID-19 Vaccines |
Language | English |
Publishing date | 2023-03-04 |
Publishing country | Switzerland |
Document type | Journal Article ; Review |
ZDB-ID | 209426-5 |
ISSN | 1421-9913 ; 0014-3022 |
ISSN (online) | 1421-9913 |
ISSN | 0014-3022 |
DOI | 10.1159/000529982 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 575: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.